ASCO Daily News: articolo in inglese della dott.ssa Cora Sternberg
Is There Sufficient Evidence to Intensify Systemic Therapy in Patients With Prostate Cancer Who Have M1 by PSMA-PET but Negative Conventional Imaging?
Key Points:
Prostate-specific membrane antigen PET scans (PSMA-PET) are more sensitive than conventional imaging (CI); however, the clinical trial data that established the standard of care for patients with metastatic hormone-sensitive prostate cancer used CI as the arbiter of decision-making.
Integrating PSMA-PET into everyday clinical practice without prospective evidence derived from clinical trials poses significant challenges to physicians as well as potential quality-of-life effects to their patients.
These challenges will only be surmounted at the completion of new and ongoing clinical trials in which PSMA-PET replaces currently accepted CI endpoints.
